Wednesday, July 8, 2026

Patent intelligence · US

US 12371414

Methods of treating neurological disorders

granted A61PA61P25/02A61P25/28
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 19
Applicant portfolio 6
Patent details — US 12371414

Quick answer

US 12371414 (Methods of treating neurological disorders) is held by Neumora Therapeutics, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
6
CPC classes
A61P, A61P25/02, A61P25/28

More from Neumora Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12247037

    1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders

    Neumora Therapeutics, Inc. · Expires Mar 6, 2045

    granted
  2. US 12171758

    Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto

    Neumora Therapeutics, Inc. · Expires Dec 19, 2044

    granted
  3. US 12152038

    Vasopressin receptor antagonists and products and methods related thereto

    Neumora Therapeutics, Inc. · Expires Nov 21, 2044

    granted
  4. US 11993580

    Methods of treating neurological disorders

    Neumora Therapeutics, Inc. · Expires May 23, 2044

    granted
  5. US 11858943

    Vasopressin receptor antagonists and products and methods related thereto

    Neumora Therapeutics, Inc. · Expires Dec 28, 2043

    granted

Frequently asked questions

What is US patent 12371414?

US 12371414 (Methods of treating neurological disorders) is held by Neumora Therapeutics, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12371414?

Neumora Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.

When does US 12371414 expire?

Our index shows an expiration date of Jul 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.